Read by QxMD icon Read


Mariana Lima, Sofia Dutra, Filipe Veloso Gomes, Tiago Bilhim, Élia Coimbra
INTRODUCTION: Hepatic transarterial chemoembolization is a widely used technique for the treatment of hepatocellular carcinoma. The most common complication of this procedure is postembolization syndrome. The main objective of this study was to assess risk factors for the development of postembolization syndrome. MATERIAL AND METHODS: Single-centre retrospective analysis of 563 hepatic transarterial chemoembolization procedures from January 1st, 2014 - December 31st, 2015...
January 31, 2018: Acta Médica Portuguesa
Valeria Palchik, María Luz Traverso, Marisel Colautti, Mariela Bianchi, Lucía Dolza, José María Catena, Mercedes Salamano
OBJECTIVE: To assess prescription of oncology medications in municipal public health network of Rosario for its appropriateness to clinical practice guidelines. METHODS: Descriptive pharmacoepidemiological study in adult patients in an Oncology Service between January and June 2012. Compliance requirements with clinical practice guidelines were evaluated. RESULTS: 51.8% of diagnoses had at least one prescription medication that did not match recommendation by at least one of the guides considered...
November 1, 2016: Farmacia Hospitalaria
Juliana Elaine Perobelli
Nowadays, the advances in knowledge about oncologic treatment have led to an increase in survival rate for cancer patients and, consequently, a growing concern about the adverse effects of treatment in medium and long term, in order to ensure the future quality of life. For male patients in reproductive age or younger, one of the key concerns after cancer therapy is their ability to father children, since anticancer drugs exert cytotoxic effects on germ cells. Considering the incidence of cancer in children and adolescents and the vulnerability of these developmental phases to chemical injuries, this review is an attempt to highlight the importance of juvenile experimental models to test new anticancer drugs and agents with protective action...
2017: Anti-cancer Agents in Medicinal Chemistry
Arnoldo Salas-Delgado, Marco Antonio Hernández-Pliego
BACKGROUND: The overall survival and relapse-free survival have increased with current chemotherapy in patients with non-lymphoma Hodgkin. A useful tool to evaluate projections is the International Prognostic Index. Our aim was to evaluate the relation between the prognosis established with the International Prognostic Index and the survival obtained in two years by patients with diffuse large B-cell lymphoma. METHODS: An observational, longitudinal, prospective study was carried out...
May 2014: Revista Médica del Instituto Mexicano del Seguro Social
G Chocarro, M V Amesty, F Hernández, B G Goiboru Chenu, R Ortíz, S Hernández, A Sánchez, M Gámez, M López Santamaría, J A Tovar
PURPOSE: Embryonal sarcoma accounts for 6 % of liver tumors. This study reviews its features and the results of treatment in a referral center. METHODS: We retrospectively reviewed liver tumors treated between 1995 and 2011. PRETEXT staging and biopsy were used to tailor chemotherapy according to SIOP protocols. Radical surgery was performed when possible. Complications and cumulative survival were the outcome endpoints. RESULTS: Six out of 156 primary liver tumors (four males and two females) were sarcomas...
December 2013: Pediatric Surgery International
Leonardo P Franchi, Nilza N Guimarães, Laise R De Andrade, Heloísa H R De Andrade, Maurício Lehmann, Rafael R Dihl, Kênya S Cunha
Noni, a Hawaiian name for the fruit of Morinda citrifolia L., is a traditional medicinal plant from Polynesia widely used for the treatment of many diseases including arthritis, diabetes, asthma, hypertension and cancer. Here, a commercial noni juice (TNJ) was evaluated for its protective activities against the lesions induced by mitomycin C (MMC) and doxorrubicin (DXR) using the Somatic Mutation and Recombination Test (SMART) in Drosophila melanogaster. Three-day-old larvae, trans-heterozygous for two genetic markers (mwh and flr3 ), were co-treated with TNJ plus MMC or DXR...
April 2013: Anais da Academia Brasileira de Ciências
Antonio González Martín
The toxicity profile of trabectedin in the OVA-301 trial, that combined trabectedin with pegylated liposomal doxorubicin for the treatment of patients with ovarian cancer, has shown to be predictable and manageable. No unexpected toxicities were found, with neutropenia and transient increase in transaminases as the most common adverse events reported. The elevation in transaminases appeared early and generally decreased in incidence and intensity over subsequent cycles, with no major clinical consequences. A similar safety profile was seen in the analysis of the older patients in the trial...
May 2011: International Journal of Gynecological Cancer
M García-Manero, M P Royo, J Espinos, L Pina, J L Alcazar, G López
BACKGROUND: Breast carcinoma during pregnancy put the health of the mother in conflict with that of the foetus. The aim is to give optimal treatment to the mother to maximise the chances of survival, whilst minimising the risk of harm of the foetus. We report the epidemiology, pathology, clinical picture, therapeutic management and foetal outcome of pregnant women with breast cancer treated in our institution. PATIENTS AND METHODS: Twenty-two pregnant breast cancer patients were treated in our hospital from January 1996 to October 2006...
February 2009: European Journal of Surgical Oncology
Sergio Gallegos-Castorena, Armando Martínez-Avalos, Alejandro Mohar-Betancourt, Guadalupe Guerrero-Avendaño, Martha Zapata-Tarrés, Aurora Medina-Sansón
UNLABELLED: Amifostine has emerged as a pancytoprotectant shown protection against nephrotoxicity, neurotoxicity and ototoxicity in preclinical studies. METHODS: We designed a prospective comparative randomized trial to evaluate the cytoprotective effects of amifostine in patients with osteosarcoma receiving cisplatin and doxorrubicin. Patients were evaluated for renal, hearing and cardiac toxicity. RESULTS: We included 28 patients, mean age was 11...
September 2007: Pediatric Hematology and Oncology
A M Andrés, L Burgos, J C López Gutiérrez, J L Encinas, M Díaz, S Rivas, Z Ros
INTRODUCTION: Morbidity of tissue extravasations is far of being properly considered in our hospitals. The increased survival rate in very low prematures and severe oncological patients has also produced an increase in the incidence of this complication, that in the most of the cases are not agressively treated in order to minimize the extravasation consequences. We have reviewed our experience in the treatment of these lessions using either injection and saline flushing of the subcutaneous (Gault tissue protocol, 1993) or coverage with artificial dermis in cases with irreversible necrosis...
July 2006: Cirugía Pediátrica: Organo Oficial de la Sociedad Española de Cirugía Pediátrica
José Luis González Vela, Jorge Martín Sánchez Guillén, Sergio Arnoldo Treviño Aguirre, David Hernández Barajas, William Orlando Brito Villanueva, Eloy Cárdenas Estrada, Juan Francisco González Guerrero
PURPOSE: In this study we evaluated the activity and toxicity of a combination of 5-fluorouracil continuous infusion and vinorelbine as second or third line chemotherapy in metastatic breast cancer (MBC). PATIENTS AN METHODS: A total 24 patients who had received doxorrubicin and/or paclitaxel were included in this study. The regimen consisted in 5-fluorouracil 1 gr/m(2) BSA continuous infusion for 3 days and vinorelbine 30 mg/m(2) intravenous (IV) on day 1. The cycles were repeated every 21 days for 6 cycles...
November 2005: Clinical & Translational Oncology
Pedro López Cubillana, Enrique Martínez Barba, Gerardo Server Pastor, Antonio Prieto González, Belén Ferri Níguez, Enrique Cao Avellaneda, Ana Isabel López López, José Antonio Nicolás Torroalba, Mariano Rigabert Montiel, Jesús Tornero Ruiz, José Antonio García Hernández, Guillermo Gómez Gómez, Pablo Martínez Pertusa, Angel Guardiola Mas, Mariano Pérez Albacete
OBJECTIVES: Report a new case of renal angiosarcoma treated by surgery and adjuvant chemotherapy with bad results. METHODS: 72-year-old male undergoing right nephrectomy for renal tumor. Pathology reports renal angiosarcoma. RESULTS: Three months after surgery patient refers lumbar pain and hemoptysis and CT scan reveals the existence of multiple bone and lung metastasis; a regimen of systemic chemotherapy with Doxorrubicine+ Ifosfamide was started without response; he died two months later...
May 2004: Archivos Españoles de Urología
Adriana Tomadoni, Diana Lombardo, Raúl Wainstein
Human epidermal growth factor receptor (HER 2) is amplified in 25 to 30% of breast cancer patients and those whose tumors demonstrate HER 2 gene amplification and protein overexpression have an inferior prognosis manifested by shorter disease-free and overall survival. Trastuzumab, the humanized murine anti-HER 2 monoclonal antibody, inhibits tumor growth when used alone and has synergistic and additive effects when used with chemotherapeutic agents (paclitacel-doxorrubicine). At the present time, the accurate diagnostic assessment of HER 2 is essential for appropriate application of the humanized anti HER 2 monoclonal antibody, trastuzumab, for the treatment of patients with metastatic breast cancer...
2004: Medicina
N Kisilevzky, L C dos Anjos, F Carnevale, C M de Souza, C de B Mott, A Laudana, A C Magalhães
Clinical manifestation of carcinoide syndrome are often difficult to control with medical treatment and so present a large problem for doctors. In the majority of cases, such manifestations are seen in patients with hepatic metastases. In such cases the control of the problem can be achieved by local hepatic treatment. A 57 year old patient with carcinoide syndrome for a year, with extensive hepatic tumor from a carcinoide tumor, whose origins were not lokted, had a urinary excretion 5-hidroxi-indolacetic = 73 mg in 24 hours, he used cyproheptadin, loperamida and metisergida without showing improvement...
July 1995: Revista do Hospital Das Clínicas
E Lobato-Mendizábal, G J Ruiz-Argüelles, J Labardini-Méndez, D Gómez-Almaguer, G Ganci-Cerrud, A Lozano-de-la-Vega
Up to now, the best treatment for patients with acute myelogenous leukemia (AML) is the induction of bone marrow hypoplasia by ablative combined chemotherapy; the prototype of these schedules is the so-called 7 + 3 (seven days of continuous infusion of cytarabine and three days of one-hour infusion of any anthracycline); these schedules require the support of both platelet transfusions and antibiotics. Other non-ablative schedules have also been tried in the treatment of such patients. Here we analyze the results of the treatment of 76 adult patients with AML; 43 were treated with the classical 7 + 3 schedule, whereas 33 were treated with a combination of chemotherapy used in non-ablative doses (TADOP: thioguanine, arabinosyl-citosine, doxorrubicin, vincristine and prednisone)...
January 1992: Revista de Investigación Clínica; Organo del Hospital de Enfermedades de la Nutrición
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"